{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:02Z","timestamp":1761870662229,"version":"build-2065373602"},"reference-count":225,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clml.2013.12.015","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T20:19:53Z","timestamp":1388780393000},"page":"284-290.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma"],"prefix":"10.1016","volume":"14","author":[{"given":"K. Martin","family":"Kortuem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Zidich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan L.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor H.","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.12.015_bib1","article-title":"Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial","volume":"118","author":"Siegel","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib2","article-title":"Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed\/refractory multiple myeloma","volume":"30","author":"Orlowski","year":"2012","journal-title":"ASCO Annu Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000205210","article-title":"Single-dose intravenous melphalan in advanced multiple myeloma","volume":"83","author":"Back","year":"1990","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1704633","article-title":"Single-agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2013.12.015_bib5","article-title":"Response adapted therapy using single-agent lenalidomide in older adults with newly diagnosed standard risk multiple myeloma","volume":"120","author":"Baz","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib6","article-title":"A\u00a0phase 1b\/2 study of prolonged infusion carfilzomib in patients with relapsed and\/or refractory (R\/R) multiple myeloma: updated efficacy and tolerability from the completed 20\/56mg\/m2 expansion cohort of PX-171-007","volume":"118","author":"Papadopoulos","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/sj.leu.2403564","article-title":"Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma","volume":"19","author":"Fenk","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib8","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib9","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2010.129","article-title":"Primary therapy with single-agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial","volume":"24","author":"Dispenzieri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C","article-title":"High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma","volume":"53","author":"Lenhard","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.12.015_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/mpo.2950130502","article-title":"Response rate and survival in myeloma patients receiving prednisone alone","volume":"13","author":"McIntyre","year":"1985","journal-title":"Med Pediatr Oncol"},{"issue":"2 Pt 1","key":"10.1016\/j.clml.2013.12.015_bib12","first-page":"345","article-title":"Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study","volume":"59","author":"Alberts","year":"1975","journal-title":"Cancer Chemother Rep"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib13","article-title":"Daratumumab, a CD38 mab, for the treatment of relapsed\/refractory multiple myeloma patients: preliminary efficacy data from a multicenter phase I\/II study","volume":"30","author":"Plesner","year":"2012","journal-title":"ASCO Annu Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib14","article-title":"SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies\u2013data from a dose-escalation phase I study","volume":"122","author":"Strickland","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1600-0609.2008.01184.x","article-title":"Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients","volume":"82","author":"Mangiacavalli","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0609.1988.tb00881.x","article-title":"High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma\u2013a pilot study from the Myeloma Group of Central Sweden (MGCS)","volume":"41","author":"Ahre","year":"1988","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00000421-199812000-00005","article-title":"Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93)","volume":"21","author":"Miller","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib18","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.12.015_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00000421-198508000-00011","article-title":"Phase II study of teniposide (VM-26) in multiple myeloma","volume":"8","author":"Tirelli","year":"1985","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib21","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2002-03-0939","article-title":"Antimyeloma efficacy of thalidomide in the SCID-hu model","volume":"100","author":"Yaccoby","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0277-5379(88)90299-4","article-title":"A\u00a0phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma","volume":"24","author":"Chisesi","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.thj.6200064","article-title":"Do anthracyclines have a role in the therapy of multiple myeloma?","volume":"1","author":"Rodjer","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2013.12.015_bib24","first-page":"11","article-title":"Studio di face II con 4-demetossidaunorubicina orale nei pazzienti anziani affetti da lifoma non Hodgkin e mieloma multiplo","author":"Errante","year":"1988","journal-title":"Folio Oncologica"},{"key":"10.1016\/j.clml.2013.12.015_bib25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/10428199909169624","article-title":"Oral idarubicin as a single-agent therapy in patients with relapsed or resistant multiple myeloma","volume":"35","author":"Sumpter","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib27","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.1985.3.11.1508","article-title":"Single-agent vincristine by infusion in refractory multiple myeloma","volume":"3","author":"Jackson","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2141.2004.04981.x","article-title":"Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects","volume":"125","author":"D'Sa","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00000421-199406000-00003","article-title":"Carboplatin in previously treated multiple myeloma. A Cancer and Leukemia Group B phase II trial","volume":"17","author":"Omura","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00873237","article-title":"Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study","volume":"12","author":"Barlogie","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib32","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/(SICI)1097-0142(19961215)78:12<2502::AID-CNCR9>3.0.CO;2-L","article-title":"High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma","volume":"78","author":"Long","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.12.015_bib33","first-page":"801","article-title":"Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial","volume":"70","author":"Gockerman","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib34","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood.V80.6.1626a.1626a","article-title":"2-Chlorodeoxyadenosine in the treatment of multiple myeloma","volume":"80","author":"Dimopoulos","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib35","first-page":"261","article-title":"Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma","volume":"16","author":"Bergsagel","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib36","first-page":"773","article-title":"Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial","volume":"71","author":"Gockerman","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00216933","article-title":"Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study","volume":"8","author":"Karanes","year":"1990","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib38","first-page":"353","article-title":"Aclarubicin in the treatment of multiple myeloma","volume":"14","author":"Sezaki","year":"1984","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib39","first-page":"1653","article-title":"Clinical responses and side effects of aclarubicin (ACR) in the treatment of multiple myeloma","volume":"10","author":"Adachi","year":"1983","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.clml.2013.12.015_bib40","first-page":"93","article-title":"Phase I-II evaluation of acronine in patients with multiple myeloma","volume":"67","author":"Scarffe","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mpo.2950170116","article-title":"Phase II trial of amsacrine in patients with multiple myeloma","volume":"17","author":"Greipp","year":"1989","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib42","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-2141.1998.00799.x","article-title":"Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma","volume":"102","author":"Grossbard","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib43","article-title":"The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study","volume":"120","author":"Shah","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2004.04941.x","article-title":"Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma","volume":"125","author":"Hussein","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib45","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/sj.leu.2403424","article-title":"A\u00a0clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients","volume":"18","author":"Rousselot","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib46","first-page":"504","article-title":"Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study","volume":"49","author":"Sanaat","year":"2011","journal-title":"Acta Med Iran"},{"issue":"suppl 2","key":"10.1016\/j.clml.2013.12.015_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.6-suppl_2-17","article-title":"Arsenic trioxide: an emerging therapy for multiple myeloma","volume":"6","author":"Munshi","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2013.12.015_bib48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","article-title":"Atacicept in relapsed\/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study","volume":"101","author":"Rossi","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2013.12.015_bib49","article-title":"A\u00a0phase I, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM)","volume":"106","author":"Wang","year":"2005","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib50","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/10428190310001628158","article-title":"Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I\/II trial","volume":"45","author":"Koskela","year":"2004","journal-title":"Leuk Lymphom"},{"key":"10.1016\/j.clml.2013.12.015_bib51","article-title":"Phase I\/IB study of AUY922 alone or with bortezomib, in patients with relapsed or refractory multiple myeloma","author":"Seggewiss-Bernhardt","year":"2012","journal-title":"EHA Annu Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib52","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2011.4","article-title":"Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single-agent and in combination with bortezomib in patients with relapsed multiple myeloma","volume":"25","author":"Moreau","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib53","article-title":"Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed\/refractory CD56-positive multiple myeloma","volume":"110","author":"Chanan-Khan","year":"2007","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib54","article-title":"A\u00a0phase II study of PXD101 in advanced multiple myeloma","volume":"108","author":"Sullivan","year":"2006","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib55","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2141.2011.08623.x","article-title":"Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed\/refractory multiple myeloma: a California Cancer Consortium trial","volume":"154","author":"Somlo","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib56","first-page":"4233","article-title":"An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma","volume":"29","author":"Kropff","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2013.12.015_bib57","first-page":"329","article-title":"Phase II evaluation of bisantrene in\u00a0refractory multiple myeloma. A Southwest Oncology Group study","volume":"9","author":"Durie","year":"1991","journal-title":"Invest New\u00a0Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib58","first-page":"1367","article-title":"Phase II study of Adriamycin and bleomycin in patients with multiple myeloma","volume":"62","author":"Bennett","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/jjco\/hym126","article-title":"Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone","volume":"37","author":"Min","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib60","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A\u00a0phase 2 study of bortezomib in\u00a0relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.12.015_bib61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A\u00a0phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib62","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1010676719178","article-title":"Phase II study of Bryostatin 1 in patients with relapsed multiple myeloma","volume":"19","author":"Varterasian","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib64","article-title":"BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed\/refractory multiple myeloma","volume":"118","author":"Jagannath","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib65","article-title":"Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed\/Refractory Multiple Myeloma","volume":"114","author":"Chanan-Khan","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib66","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A\u00a0phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib67","article-title":"Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma","volume":"120","author":"Lendvai","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib68","article-title":"Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"27","author":"Jagannath","year":"2009","journal-title":"ASCO Annu Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib69","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib70","article-title":"Phase I study of carfilzomib in patients (pts) with relapsed and refractory multiple myeloma (MM) and varying degrees of renal insufficiency","volume":"114","author":"Badros","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib71","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A\u00a0phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.015_bib72","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A\u00a0phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.015_bib73","article-title":"High-dose cyclophosphamide vs CCNU treatment of melphalan resistant myeloma","author":"Mass","year":"1976","journal-title":"Proc Am Assoc Cancer Res and ASCO"},{"key":"10.1016\/j.clml.2013.12.015_bib74","article-title":"A\u00a0phase II clinical trial of the anti-EGFR Antibody cetuximab in patients with refractory or relapsed multiple myeloma: final results","volume":"118","author":"von Tresckow","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib75","first-page":"1409","article-title":"Phase II evaluation of chlorozotocin in refractory multiple myeloma","volume":"68","author":"Forman","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib76","first-page":"685","article-title":"Chlorozotocin: phase II evaluation in patients with myeloma","volume":"68","author":"Cornell","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib77","first-page":"1857","article-title":"Phase Ib study of recombinant circularly permuted trail (CPT) in relapsed or refractory multiple myeloma patients","volume":"120","author":"Chen","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V93.12.4441","article-title":"Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma","volume":"93","author":"Stewart","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib79","first-page":"658","article-title":"Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report","volume":"87","author":"Musto","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.12.015_bib80","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/sj.leu.2401332","article-title":"Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Francais du Myelome (IFM)","volume":"13","author":"Moreau","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib81","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2141.1998.00835.x","article-title":"Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study","volume":"102","author":"van Zaanen","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib82","first-page":"1581","article-title":"The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma","volume":"91","author":"Uy","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.12.015_bib83","article-title":"High-dose cyclophosphamide: an effective non-transplant salvage option in relapsed\/refractory multiple myeloma","volume":"114","author":"Ailawadhi","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib84","article-title":"Continuous infusion cyclophosphamide as salvage therapy for relapsed or refractory multiple myeloma","volume":"114","author":"Malhotra","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib85","first-page":"851","article-title":"Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide","volume":"107","author":"Bergsagel","year":"1972","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.clml.2013.12.015_bib86","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jama.1964.03070100052010","article-title":"Multiple Myeloma. Ii. Analysis of Cyclophosphamide Therapy in 165 Patients","volume":"189","author":"Korst","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2013.12.015_bib87","article-title":"Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: results of a phase I\/II study","volume":"110","author":"Vadhan-Raj","year":"2007","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib88","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","article-title":"A\u00a0phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma","volume":"95","author":"Hussein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.12.015_bib89","article-title":"Daratumumab, A CD38 monoclonal antibody study in advanced multiple myeloma\u2014an open-label, dose escalation followed by open-label extension in a single-arm phase I\/II study","author":"Lokhorst","year":"2013","journal-title":"EHA Ann Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10428190802563363","article-title":"Dasatinib in relapsed or plateau-phase multiple myeloma","volume":"50","author":"Wildes","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib91","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma","volume":"84","author":"Vij","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2013.12.015_bib92","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.12.015_bib93","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-105-1-8","article-title":"High-dose glucocorticoid treatment of resistant myeloma","volume":"105","author":"Alexanian","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2013.12.015_bib94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.2830360303","article-title":"High-dose dexamethasone for refractory or relapsing multiple myeloma","volume":"36","author":"Friedenberg","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2013.12.015_bib95","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib96","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib97","first-page":"1095","article-title":"Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study","volume":"71","author":"Stuckey","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00873234","article-title":"A\u00a0phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study","volume":"12","author":"Weiss","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib99","article-title":"Phase 1\/2 trial of a novel CDK Inhibitor dinaciclib (SCH727965) in patients with relapsed multiple myeloma demonstrates encouraging single-agent activity","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0145-2126(02)00344-2","article-title":"The treatment of multiple myeloma with docetaxel (an ECOG study)","volume":"27","author":"Friedenberg","year":"2003","journal-title":"Leuk Res"},{"issue":"suppl 18","key":"10.1016\/j.clml.2013.12.015_bib101","article-title":"Phase I trial of chir-258 in multiple myeloma","volume":"24","author":"Lonial","year":"2006","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib102","article-title":"A\u00a0phase 2 multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation","volume":"120","author":"Scheid","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X","article-title":"Phase II evaluation of Adriamycin in human neoplasia","volume":"32","author":"O'Bryan","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.12.015_bib104","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A\u00a0phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib105","article-title":"Clinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma: interim phase I trial results","volume":"116","author":"Farag","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib106","first-page":"6246","article-title":"Phase I-II study of epirubicin in multiple myeloma","volume":"48","author":"Case","year":"1988","journal-title":"Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib107","article-title":"Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study","volume":"28","author":"Guenther","year":"2010","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib108","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1200\/JCO.2007.15.9319","article-title":"Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma","volume":"26","author":"Lacy","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib109","first-page":"390","article-title":"Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points","volume":"91","author":"Dispenzieri","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.12.015_bib110","article-title":"Phase I trial of flavopiridol in relapsed myeloma: brief response in t(4;14) with significant neutropenia","volume":"116","author":"Hofmeister","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib111","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00177259","article-title":"Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study","volume":"8","author":"Kraut","year":"1990","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib112","article-title":"A\u00a0Phase 1 trial of fluphenazine HCl (Fz), a serotonin antagonist, in relapsed and refractory multiple myeloma","volume":"112","author":"Stadtmauer","year":"2008","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib113","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/annonc\/mdg158","article-title":"Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients","volume":"14","author":"Dumontet","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib114","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/10428190290026330","article-title":"Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma","volume":"43","author":"Offidani","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1014493007347","article-title":"The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study","volume":"20","author":"Weick","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib116","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","article-title":"A\u00a0phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma","volume":"89","author":"Galli","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2013.12.015_bib117","article-title":"Novel AKT inhibitor GSK2110183 shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Preliminary results from a phase I first-time-in-human study","volume":"118","author":"Spencer","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib118","first-page":"51","article-title":"Phase II studies of hydroxyurea (Nsc-32065) in adults: multiple myeloma and lymphoma","volume":"40","author":"Davis","year":"1964","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib119","volume":"118","author":"Lust","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10428190500271269","article-title":"A\u00a0phase II trial of imatinib in patients with refractory\/relapsed myeloma","volume":"47","author":"Dispenzieri","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib121","article-title":"Imexon (AOP 99.0001) for treatment of relapsed or refractory multiple myeloma: a phase I\/II study","volume":"112","author":"Moehler","year":"2008","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib122","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0277-5379(86)90015-5","article-title":"Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial","volume":"22","author":"Ludwig","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib123","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood.V67.2.275.275","article-title":"Treatment of multiple myeloma with recombinant alpha-interferon","volume":"67","author":"Quesada","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib124","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.1985.3.5.654","article-title":"Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma","volume":"3","author":"Costanzi","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib125","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.leukres.2009.01.020","article-title":"Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group","volume":"33","author":"Lacy","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.12.015_bib126","article-title":"IPH2101, a novel anti-inhibitory KIR monoclonal antibody for multiple myeloma: interim phase 1 Trial results and correlative biologic and safety data","volume":"116","author":"Benson","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib127","article-title":"A\u00a0phase II trial of IPH2101 (anti-KIR mAb) in smoldering multiple myeloma","volume":"118","author":"Korde","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib128","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3109\/10428194.2011.600481","article-title":"A\u00a0phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma","volume":"52","author":"Siegel","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cncr.11480","article-title":"A\u00a0phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma","volume":"98","author":"Agrawal","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.12.015_bib130","article-title":"PEG-L-asparaginase (PL-A) in advanced multiple myeloma (MM): clinical results","author":"Hussein","year":"1997","journal-title":"ASCO Annu Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib131","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib132","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib133","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A\u00a0randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib134","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428191003721342","article-title":"Single-agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis","volume":"51","author":"Baz","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"suppl","key":"10.1016\/j.clml.2013.12.015_bib135","first-page":"8080","article-title":"Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial","volume":"29","author":"Buadi","year":"2011","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib136","article-title":"Efficacy analysis from phase I Study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated cd56-positive multiple myeloma - a preliminary efficacy analysis","volume":"116","author":"Chanan-Khan","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib137","article-title":"A\u00a0phase 1 dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma","volume":"108","author":"Bensinger","year":"2006","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib138","article-title":"Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed\/refractory multiple myeloma (MM)","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib139","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM)","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib140","article-title":"FGFR3 tyrosine kinase inhibitor AB1010 as treatment of t(4;14) multiple myeloma","volume":"110","author":"Arnulf","year":"2007","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib141","article-title":"A\u00a0phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients","volume":"28","author":"Spencer","year":"2010","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib142","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0277-5379(83)90113-X","article-title":"Intermittent high-dose melphalan\/prednisone vs continuous low-dose melphalan treatment in multiple myeloma","volume":"19","author":"Ahre","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib143","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2013.12.015_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V31.1.1.1","article-title":"Melphalan therapy for plasma cell myeloma","volume":"31","author":"Alexanian","year":"1968","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01275478","article-title":"Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University","volume":"10","author":"Cruz","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib146","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00000421-200008000-00014","article-title":"Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia","volume":"23","author":"Kucuk","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib147","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1158\/1078-0432.CCR-07-0807","article-title":"Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma","volume":"13","author":"Rajkumar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.015_bib148","article-title":"A\u00a0phase I study of the safety and pharmacokinetics of escalating doses of MFGR1877S, a fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with relapsed or refractory T(4;14)-positive multiple myeloma","author":"Trudel","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib149","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/07357909009017559","article-title":"Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study","volume":"8","author":"Winter","year":"1990","journal-title":"Cancer Invest"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib150","article-title":"Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma","volume":"27","author":"Kaufman","year":"2009","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib151","first-page":"669","article-title":"Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial","volume":"70","author":"Esseesse","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib152","first-page":"1321","article-title":"Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study","volume":"69","author":"Alberts","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib153","article-title":"Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and\/or refractory multiple myeloma or lymphoma","volume":"116","author":"Shah","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib154","article-title":"Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed\/refractory multiple myeloma (MM): A phase I study","volume":"30","author":"Kumar","year":"2012","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib155","article-title":"Investigational AGENT MLN9708, an oral proteasome inhibitor, in patients (pts) with relapsed and\/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib156","article-title":"Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and\/or refractory multiple myeloma (MM)","volume":"30","author":"Lonial","year":"2012","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib157","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1158\/1078-0432.CCR-04-0747","article-title":"Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (CellCept) in advanced multiple myeloma patients","volume":"10","author":"Takebe","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.clml.2013.12.015_bib158","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/BF00171990","article-title":"A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study","volume":"8","author":"Edelstein","year":"1990","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib159","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/oxfordjournals.annonc.a058982","article-title":"Primary therapy of multiple myeloma with paclitaxel (Taxol)","volume":"5","author":"Dimopoulos","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib160","article-title":"A\u00a0Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma","volume":"112","author":"Wolf","year":"2008","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib161","article-title":"Phase IA\/II study of oral panobinostat (LBH589), a novel pan- deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies","volume":"112","author":"Ottmann","year":"2008","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib162","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1182\/blood-2009-02-207209","article-title":"Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)","volume":"113","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib163","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/jnci\/82.22.1778","article-title":"Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study","volume":"82","author":"Grever","year":"1990","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2013.12.015_bib164","article-title":"Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed\/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib165","first-page":"1617","article-title":"Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study","volume":"61","author":"Jones","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib166","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-10-0469","article-title":"Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma","volume":"16","author":"Mateos","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.015_bib167","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":"Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in\u00a0vivo immunomodulation","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib168","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib169","article-title":"Pomalidomide monotherapy for relapsed myeloma is associated with excellent responses and prolonged progression free and overall survival","volume":"114","author":"Streetly","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib170","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib171","first-page":"537","article-title":"Prednimustine in elderly patients with multiple myeloma: a phase II study","volume":"70","author":"Tirelli","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib172","first-page":"257","article-title":"A\u00a0comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma","volume":"16","author":"Mass","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib173","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V62.3.572.572","article-title":"Prednisone pulse therapy for refractory myeloma","volume":"62","author":"Alexanian","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib174","first-page":"179","article-title":"Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma","volume":"51","author":"Salmon","year":"1967","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib175","first-page":"2115","article-title":"A\u00a0phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma","volume":"9","author":"Gertz","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib176","first-page":"1403","article-title":"Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy","volume":"63","author":"Lake-Lewin","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2013.12.015_bib177","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.leu.2404558","article-title":"Rituximab in CD20 positive multiple myeloma","volume":"21","author":"Moreau","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib178","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/10428190600564803","article-title":"Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma","volume":"47","author":"Zojer","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib179","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.12.015_bib180","article-title":"Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I\/II study","volume":"120","author":"Raje","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib181","article-title":"Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM)","volume":"108","author":"Siegel","year":"2006","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib182","article-title":"A\u00a0phase II study of the MEK 1\/2 inhibitor AZD6244 (selumetinib, ARRY-142866) in relapsed or refractory multiple myeloma","volume":"118","author":"Holkova","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib183","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1078-0432.CCR-0221-3","article-title":"Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma","volume":"10","author":"Zangari","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.015_bib184","article-title":"Preliminary results of a phase I study of the pan-PI3 kinase inhibitor SF1126 in patients with relapsed and refractory myeloma","volume":"114","author":"Lonial","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"suppl 15","key":"10.1016\/j.clml.2013.12.015_bib185","first-page":"e19517","article-title":"A\u00a0phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434)","volume":"27","author":"Srkalovic","year":"2009","journal-title":"ASCO Annu Meet Abstr"},{"key":"10.1016\/j.clml.2013.12.015_bib186","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib187","article-title":"A\u00a0phase II trial of sunitinib (SU11248) in multiple myeloma","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib188","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/djh108","article-title":"Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma","volume":"96","author":"Decaudin","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2013.12.015_bib189","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2010.08265.x","article-title":"Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib190","article-title":"A\u00a0phase II trial of TBL 12 Sea cucumber extract in patients with untreated asymptomatic myeloma","volume":"118","author":"Chari","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib191","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.leukres.2009.01.039","article-title":"Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma","volume":"33","author":"Farag","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.12.015_bib192","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib193","first-page":"404","article-title":"Thalidomide treatment of resistant or relapsed multiple myeloma patients","volume":"86","author":"Hus","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.12.015_bib194","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","article-title":"Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma","volume":"109","author":"Juliusson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.thj.6200175","article-title":"Thalidomide in patients with advanced multiple myeloma: a study of 83 patients\u2014report of the Intergroupe Francophone du Myelome (IFM)","volume":"3","author":"Yakoub-Agha","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2013.12.015_bib196","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0145-2126(03)00027-4","article-title":"An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment","volume":"27","author":"Schey","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.12.015_bib197","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000092352","article-title":"Very low doses of thalidomide as single-agent in relapsed\/refractory multiple myeloma","volume":"116","author":"Guglielmelli","year":"2006","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib198","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.21821","article-title":"Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma","volume":"85","author":"Detweiler-Short","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2013.12.015_bib199","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0248-8663(00)00279-4","article-title":"Thalidomide: the revival","volume":"22","author":"Grosbois","year":"2001","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.clml.2013.12.015_bib200","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.12.015_bib201","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2783.x","article-title":"Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration","volume":"77","author":"Cibeira","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib202","first-page":"3377","article-title":"Dose-dependent effect of thalidomide on\u00a0overall survival in relapsed multiple myeloma","volume":"8","author":"Neben","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.12.015_bib203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2004.04879.x","article-title":"Early response predicts thalidomide efficiency in patients with advanced multiple myeloma","volume":"125","author":"Waage","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib204","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2002-05-1527","article-title":"Efficacy of a low dose of thalidomide in advanced multiple myeloma","volume":"100","author":"Leleu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib205","first-page":"1","article-title":"Efficacy of low dose thalidomide in multiple myeloma","volume":"1","author":"Durie","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.clml.2013.12.015_bib206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(00)90079-9","article-title":"Thalidomide for resistant and relapsing Myeloma","volume":"37","author":"Alexanian","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2013.12.015_bib207","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2002-09-2846","article-title":"Multicenter phase 2 trial of thalidomide in relapsed\/refractory multiple myeloma: adverse prognostic impact of advanced age","volume":"102","author":"Mileshkin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib208","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.12.015_bib209","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4065\/78.1.34","article-title":"Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.12.015_bib211","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.12.015_bib212","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib213","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.12.015_bib214","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1600-0609.2004.00238.x","article-title":"Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy","volume":"72","author":"Offidani","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.12.015_bib215","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4065\/79.7.875","article-title":"Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity","volume":"79","author":"Richardson","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.12.015_bib216","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2003-08-2764","article-title":"Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic\/tumor survival pathways in patients with advanced multiple myeloma","volume":"103","author":"Alsina","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib217","article-title":"Phase II study of the CET inhibitor RQ 197 (tivantinib) in patients with relapsed multiple myeloma","volume":"120","author":"Dorkhom","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.clml.2013.12.015_bib218","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1998.16.2.589","article-title":"Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study","volume":"16","author":"Kraut","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib219","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10428190600909578","article-title":"A\u00a0phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma","volume":"48","author":"Vose","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib220","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V27.3.328.328","article-title":"A\u00a0controlled trial of urethane treatment in multiple myeloma","volume":"27","author":"Holland","year":"1966","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.12.015_bib221","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3109\/10428194.2010.488709","article-title":"Efficacy and tolerability of PTK787\/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant","volume":"51","author":"Vij","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.12.015_bib222","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-006-9022-7","article-title":"A\u00a0phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma\u2014NCIC CTG IND.145","volume":"24","author":"Kovacs","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.12.015_bib223","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-2964(81)90040-2","article-title":"Vindesine therapy in melphalan-resistant multiple myeloma","volume":"17","author":"Houwen","year":"1981","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2013.12.015_bib224","article-title":"An alternative treatment for relapsed\/resistant multiple myeloma (MM): vinorelbine (VRL), plus high-dose dexamethasone (DEX): two phase II studies","volume":"8","author":"Harousseau","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2013.12.015_bib225","article-title":"Phase II optimization, open-label clinical trial of Zalypsis (PM00104) in relapsed\/refractory multiple myeloma patients","volume":"120","author":"Ocio","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013005296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013005296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:13Z","timestamp":1761870373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013005296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":225,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2152265013005296"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.12.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}